Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-25-004068
Filing Date
2025-07-11
Accepted
2025-07-11 12:30:10
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8089
2 d11848978_ex99-a.htm EX-99 3094
3 d11848978_ex99-b.htm EX-99 919
  Complete submission text file 0000919574-25-004068.txt   14124
Mailing Address 152 WEST 57TH STREET 50TH FLOOR NEW YORK NY 10019
Business Address 152 WEST 57TH STREET 50TH FLOOR NEW YORK NY 10019 212-333-0100
KINGDON CAPITAL MANAGEMENT, L.L.C. (Filed by) CIK: 0001000097 (see all company filings)

EIN.: 134015739 | State of Incorp.: DE
Type: SCHEDULE 13G

Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Subject) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91228 | Film No.: 251118236
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)